Testing a new drug for rare kidney and bladder cancers
Treatments studied
Part of Cancer, Kidney & urinary clinical trials.
This trial tests a new drug (sacituzumab tirumotecan) for people with rare types of kidney or bladder cancer that have spread. The drug targets a protein called TROP-2 on cancer cells. The goal is to see if it can shrink tumors or slow the cancer when other treatments have stopped working or are not available.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have either papillary kidney cancer that has spread, or a rare type of bladder cancer (called variant histology) that cannot be removed by surgery.
- Your cancer got worse after standard treatment, or there is no standard treatment for your specific type.
- You are at least 18 years old and able to do normal daily activities with little or no help (ECOG 0 or 1).
- You have a tumor sample available from a biopsy or surgery for testing.
- Your kidneys, liver, and blood counts are within safe limits as checked by blood tests.
- You are not pregnant or breastfeeding, and agree to use effective birth control if applicable.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial is for people with advanced bladder cancer (urothelial cancer) that has spread or can't be removed. It tests a new drug called sacituzumab tirumotecan against standard chemotherapy options to see if it works better.
This trial tests a new drug called sacituzumab tirumotecan for people with low-grade bladder cancer that hasn't spread into the bladder muscle. The goal is to see if it can help shrink or control the tumors.
This trial tests sacituzumab govitecan, an anti-cancer drug, for people with urothelial (bladder/urinary tract) cancer that has spread or can’t be removed with surgery. It’s designed for tumors that have been treated already in specific ways, to see if the medicine can shrink or control the cancer.
This Phase 1 study tests whether a new bladder-cancer treatment plan—radiation given at the same time as sacituzumab govitecan—can help people with muscle-invasive bladder cancer without starting with traditional chemo/radiation. Because it’s early-stage, the main goal is safety and learning the best way to use this combination to preserve the bladder.
This trial tests a new targeted drug, sacituzumab tirumotecan, for people with advanced small bowel adenocarcinoma that has not responded to or cannot tolerate platinum-based chemotherapy. The drug targets a protein called TROP2 on cancer cells to deliver treatment directly to them.
This trial tests an investigational drug called sacituzumab tirumotecan for a rare and aggressive type of kidney cancer called renal medullary carcinoma (RMC) or a related variant. The drug is designed to target and deliver treatment directly to cancer cells. The study aims to see if it can shrink tumors or slow the disease in people who have already tried other treatments.
Hear when a new Papillary Renal Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.